Tenet director sells 12,010 shares at ~$264

TENET HEALTHCARE CORP (THC) director Robert J. Kerrey reported selling a total of 12,010 shares of common stock on September 14, 2026 in three open-market transactions.

Rhea-AI Filing Summary

TENET HEALTHCARE CORP (THC) director Robert J. Kerrey reported selling a total of 12,010 shares of common stock on September 14, 2026 in three open-market transactions. The weighted average prices for these sales were about $263.04, $264.10, and $264.62 per share, each executed over stated intraday price ranges. No Rule 10b5-1 trading plan is indicated.

Insider Trade Summary

Net Seller: 12,010 shares

Net Sell 3 txns

Insider KERREY J ROBERT

Role Director

Sold 12,010 shs ($3.17M)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	5,483	$263.04	$1.44M
Sale	Common Stock F2	4,025	$264.10	$1.06M
Sale	Common Stock F3	2,502	$264.62	$662K

Holdings After Transaction: Common Stock — 4,794 shares (Direct)

Footnotes (3)

1. F1. The price is the weighted average sales price of the aggregate number of shares that were sold by the reporting person. These shares were sold in multiple transactions at prices ranging from $262.43 to $263.37.
2. F2. The price is the weighted average sales price of the aggregate number of shares that were sold by the reporting person. These shares were sold in multiple transactions at prices ranging from $263.45 to $264.44.
3. F3. The price is the weighted average sales price of the aggregate number of shares that were sold by the reporting person. These shares were sold in multiple transactions at prices ranging from $264.45 to $265.02.

Key Figures

Total shares sold: 12,010 shares Shares sold tranche 1: 5,483 shares Weighted average price tranche 1: $263.04 per share +4 more

7 metrics

Total shares sold 12,010 shares Aggregate common shares sold by the director on September 14, 2026

Shares sold tranche 1 5,483 shares Common stock sold at a weighted average price of $263.04 on September 14, 2026

Weighted average price tranche 1 $263.04 per share First reported sale; individual trades ranged from $262.43 to $263.37

Shares sold tranche 2 4,025 shares Common stock sold at a weighted average price of $264.10 on September 14, 2026

Weighted average price tranche 2 $264.10 per share Second reported sale; trades ranged from $263.45 to $264.44

Shares sold tranche 3 2,502 shares Common stock sold at a weighted average price of $264.62 on September 14, 2026

Weighted average price tranche 3 $264.62 per share Third reported sale; trades ranged from $264.45 to $265.02

Key Terms

weighted average sales price, open market or private transaction, Rule 10b5-1

3 terms

weighted average sales price financial

"The price is the weighted average sales price of the aggregate number of shares"

open market or private transaction financial

"Sale in open market or private transaction"

Rule 10b5-1 regulatory

"No Rule 10b5-1 trading plan is indicated"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did THC disclose in this Form 4?

The filing reports that director Robert J. Kerrey sold 12,010 shares of Tenet Healthcare common stock on September 14, 2026 in three open-market transactions at weighted average prices around $263–$265 per share.

Who is the insider involved in the September 14, 2026 THC stock sale?

The insider is Robert J. Kerrey, a director of Tenet Healthcare Corp. He reported three open-market sales of the company’s common stock on September 14, 2026.

How many THC shares did the director sell on September 14, 2026?

Across three transactions, the director sold a total of 12,010 shares of Tenet Healthcare common stock, as shown in the Form 4 transaction summary.

At what prices were the 12,010 THC shares sold?

The reported weighted average sale prices were $263.04 for 5,483 shares, $264.10 for 4,025 shares, and $264.62 for 2,502 shares. Footnotes state these were executed in multiple trades within ranges from $262.43 to $265.02.

Were the September 14, 2026 THC stock sales under a Rule 10b5-1 plan?

No. The document-level Rule 10b5-1 checkbox is not marked, and the footnotes do not state that these transactions were made under a Rule 10b5-1 or other pre-arranged trading plan.

Are the sales reported as direct or indirect holdings of THC shares?

All three sales are reported as direct transactions in Tenet Healthcare common stock, with the ownership type shown as direct and no separate entity listed in the nature of ownership field.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/16/2026 - 08:00 PM Accepted by SEC EDGAR 09/16/2026 - 08:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KERREY J ROBERT

(Last) (First) (Middle)

14201 DALLAS PARKWAY

(Street)

DALLAS TEXAS 75254

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TENET HEALTHCARE CORP [ THC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/14/2026		S		5,483	D	$263.04(1)	11,321	D
Common Stock	09/14/2026		S		4,025	D	$264.1(2)	7,296	D
Common Stock	09/14/2026		S		2,502	D	$264.62(3)	4,794	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price is the weighted average sales price of the aggregate number of shares that were sold by the reporting person. These shares were sold in multiple transactions at prices ranging from $262.43 to $263.37.

2. The price is the weighted average sales price of the aggregate number of shares that were sold by the reporting person. These shares were sold in multiple transactions at prices ranging from $263.45 to $264.44.

3. The price is the weighted average sales price of the aggregate number of shares that were sold by the reporting person. These shares were sold in multiple transactions at prices ranging from $264.45 to $265.02.

	Chad J. Wiener, as Attorney-in-Fact for J. Robert Kerrey	09/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)